Leadership team expanded with addition of Chief Corporate Development Officer, Ted Hibben, a 25-year venture-stage business development biotherapeutic industry veteran
Total venture funding tops $50M to date
Amelia™-1 Study is testing if evexomostat can improve patients' safety and clinical response to a PI3K inhibitor plus an estrogen receptor degrader. Evexomostat, a novel MetAP2 inhibitor, controlled PI3K-induced hyperglycemia in the first study patient, consistent with pre-clinical data. Further, ctDNA data shows no evidence of residual PIK3CA mutation in blood after 6 weeks of treatment.
Read Press ReleaseBrainify.AI, an innovative company leveraging artificial intelligence to revolutionize the treatment of depression, is excited to announce it has joined Johnson & Johnson Innovation JLABS (JLABS) as a resident company. This marks a significant milestone for Brainify.AI and is another indication of the value and promise the company brings to the medical AI field.
Read Press ReleaseA University of Chicago team identified a special type of stem cell that heals damaged bowel tissue in mice, a discovery that may have direct application to humans with inflammatory bowel disease. These early findings, made possible with seed funding from the GI Research Foundation, resulted in a recent five-year, $2.5 million grant from the National Institutes of Health to study those cells in humans.
Read Press ReleaseCMX-2043, a novel, proprietary cytoprotective drug candidate, demonstrated excellent safety and tolerability in a Phase 1 single ascending and multiple ascending dose (SAD-MAD) clinical trial. CMX-2043 has previously demonstrated safety and efficacy in extensive preclinical pharmacology, toxicology and TBI translational studies. CMX-2043 will be Phase 2-ready by the first quarter of 2024.
Read Press ReleasePA-based clinical technology provider assisTek has announced new features to its upcoming software release, including AI Integration, a Proprietary OS, SSO & Remote Provisioning, to add to its growing suite of eCOA & ePRO solutions.
Read Press ReleaseIn a clinical validation study published on Scientific Reports, UNITY RhD NIPT and Fetal antigen NIPT demonstrated 100% sensitivity, 100% specificity, 99.9% precision with 0.1% no-call rate across 3,921 NIPT assays.
Read Press Release